Judge Allows Abortion Pill Dispensing by Mail for Now

Ruling blocks Louisiana's attempt to halt mail-order access to mifepristone.

Apr. 7, 2026 at 9:33pm

Got story updates? Submit your updates here. ›

A photorealistic painting of a lone mailbox on a residential street, with warm sunlight casting deep shadows across the scene, conceptually representing the ongoing legal battle over access to abortion pills by mail.A court ruling maintains mail-order access to abortion medication, though the long-term status of the regulations remains uncertain.Lafayette Today

A federal judge in Louisiana has refused to block the FDA's rules allowing the abortion drug mifepristone to be dispensed by mail to people with prescriptions. The ruling is a setback for the state's effort to restrict access to the pill in areas where abortion is banned.

Why it matters

This decision maintains access to medication abortion through mail-order services, which has become an important option in states with strict abortion laws. However, the judge warned the FDA that it must complete its review of the drug's safety and efficacy.

The details

U.S. District Judge David Joseph, based in Lafayette, Louisiana, ruled against the state's Attorney General Liz Murrill, who had asked the court to pause the FDA's 2023 regulations allowing mifepristone to be dispensed by mail while a legal challenge to those rules proceeds.

  • On April 7, 2026, Judge Joseph issued his ruling.

The players

David Joseph

A U.S. District Judge based in Lafayette, Louisiana.

Liz Murrill

The Attorney General of Louisiana who sought to block the FDA's mail-order mifepristone rules.

U.S. Food and Drug Administration

The federal agency that regulates and oversees the approval of prescription drugs like mifepristone.

Got photos? Submit your photos here. ›

What’s next

The legal challenge to the FDA's mifepristone regulations will continue to move through the courts.

The takeaway

This ruling maintains access to medication abortion through mail-order services, which has become an important option in states with strict abortion laws. However, the judge's warning to the FDA suggests ongoing scrutiny of the drug's status.